Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Jeong Heo
No relevant relationships to disclose
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Mong Cho
No relevant relationships to disclose
Tae-Ho Hwang
Consultant or Advisory Role - Jennerex Biotherapeutics (U)
Stock Ownership - Jennerex Biotherapeutics
Research Funding - Jennerex Biotherapeutics
Chang Won Kim
No relevant relationships to disclose
Ung Bae Jeon
No relevant relationships to disclose
Hyun Young Woo
No relevant relationships to disclose
Ki Tae Yoon
No relevant relationships to disclose
Jun Woo Lee
No relevant relationships to disclose
James Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Theresa Hickman
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Lara Longpre
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Richard H. Patt
Consultant or Advisory Role - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics